




## Supplementary Material




**Figure S1.** Spontaneous scratching behaviors of AEW-treated mice on days 1, 3, and 5. \*  $p < 0.05$




**Figure S2.** (a) Transcriptional levels of IL-13 in the skin of HC067047-administered AEW ICR mice administered by HC067047 (“+HC067”) vs. control groups (n = 3) (b) Transcriptional levels of IL-13 in the skin of different genotypes (n = 3) (c) Serum levels of IL-13 between AEW-treated and control mice (n = 3) (d) Transcriptional levels of IL-33 in the skin of AEW ICR mice (“+HC067”) vs. control groups (n = 3) (e) Transcriptional levels of IL-33 in the skin of different genotypes (n = 3) (f) Serum levels of IL-33 between AEW-treated and control mice (n = 3) (g) serum levels of TNF- $\alpha$  (n = 4) between AEW-treated and control mice. (h) The transcriptional changes in *Aqp3* and *Tslp* in murine keratinocytes on day 5 after treatment with AEW. \*\*\*  $p < 0.001$ , n.s. not significant




**Figure S3.** The effect of HC067047 administration (“+HC067”) on the skin lesion scores (a), TEWL (b), skin thickness (c), and spontaneous scratching bouts (d) between control and AEW-treated mice. \*  $p < 0.05$




**Figure S4.** Comparisons of *Trpv4* levels in the skin (a) and the DRG among different *Trpv4* genotype mice. Differences in skin lesion scores (c), TEWL (d), skin thickness (e) and spontaneous scratching bouts (f) between different *Trpv4* genotype mice. \*  $p < 0.05$ , ND: not detected



**Figure S5.** Effect of AEW treatment on spontaneous scratching behaviors of different strains of mice (ICR vs. C57BL/6). There were no significant differences between the spontaneous scratching behaviors of the two strains ( $n = 4\sim 6$  per group).



**Figure S6.** (A) Pretreatment with 100  $\mu$ M HC030031, a specific TRPA1 antagonist, significantly inhibited the peak responses induced by 5 ng/mL TSLP in the DRG neurons of AEW-treated mice ( $n = 65$ ), in comparison to those of the control ( $n = 27$ ). (B) Pretreatment with 10  $\mu$ M capsaizepine, a TRPV1 antagonist, produced no differences in the peak responses induced by TSLP in the DRG neurons of AEW-treated mice ( $n = 15$ ), in comparison to those of the control ( $n = 27$ ). \*\*\*  $p < 0.001$ , n.s. not significant.



**Figure S7.** The average number of mast cells in ICR ( $170.3 \pm 9.528$ ,  $n = 3$ ) and C57BL/6 mice ( $165.3 \pm 13.53$ ,  $n = 3$ ) did not differ significantly.

**Table S1. Sequences of the forward and reverse primers used for RT-qPCR.**

| Gene         | Forward primer               | Reverse primer               |
|--------------|------------------------------|------------------------------|
| <i>Gapdh</i> | 5'-AGGTCGGTGTGAACGGATTT-3'   | 5'-TGTAGACCATGTAGTTGAGG-3'   |
| <i>Tslp</i>  | 5'-ACGGATGGGGCTAACTTACAA-3'  | 5'-AGTCCTCGATTTGCTCGAACT-3'  |
| <i>Tslpr</i> | 5'-CCCACCTTGGAATGTGACG-3'    | 5'-CCGGAAGTCATAGCAGCGT-3'    |
| <i>Trpv4</i> | 5'-ATGGCAGATCCTGGTGATGG-3'   | 5'-GGAAC TTCATACGCAGGTTTG-3' |
| <i>Trpv3</i> | 5'-ACGGTCACCAAGACCTCTC-3'    | 5'-GACTGTTGGGATTGGATGGGG-3'  |
| <i>Par2</i>  | 5'-TCCGGTAGAACCAGGCTTTTC-3'  | 5'-GGGCAAACCAATCACAAACAC-3'  |
| <i>IL-33</i> | 5'-TCCAAC TCCAAGATTTCCCCG-3' | 5'-CATGCAGTAGACATGGCAGAA-3'  |
| <i>IL-13</i> | 5'-CCTGGCTCTTGCTTGCCTT-3'    | 5'-GGTCTTGTGTGATGTTGCTCA-3'  |